drugset / Trial / NCT01523301

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

NCT01523301

Phase 4 Completed 380 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

Timeline

Start
2012-04
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 8 mg Other
Subject Rotigotine Unknown 16 mg Other

Indications